Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
701-720 of 936 trials

Activated T-Cells for Graft vs Host Disease After Stem Cell Transplant

We are testing a new treatment using activated regulatory T-cells in patients shortly after stem cell transplantation. The aim is to see if it can safely reduce the risk and severity of acute graft vs host disease.

LeukaemiaAcute graft versus host disease1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Advanced Solid Tumors: BMS-986482 Study

We are investigating the safety and dosage of BMS-986482 alone or with other therapies for patients with advanced solid tumors. This study aims to understand how well it works in combination with existing treatments.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Advanced Liver Cancer: BAY 3547926 Study

We are investigating the safety and effectiveness of a new drug, BAY 3547926, for people with advanced liver cancer. This study aims to understand how well it works in treating this condition.

Liver Cancer>2 yearsSafety phase (I)HepatologyOncology

Eosinophilic Esophagitis: EP 104GI Treatment Study

We are testing a new treatment called EP 104GI for adults with eosinophilic esophagitis. The study aims to evaluate its safety and effectiveness in reducing symptoms and improving esophageal health.

Eosinophilic Esophagitis1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesAllergologyGastroenterology

Sjögren's Syndrome: Stem Cell Treatment for Dry Mouth

We are studying whether injecting stem cells into the salivary glands can improve saliva flow in patients with dry mouth from Sjögren's syndrome. This trial will also assess safety and other effects on saliva quality.

Sjögren's Syndrome≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesOrthopedics and TraumatologyRheumatology

Sublingual Vaccine: Trained Immunity Study

We are investigating whether a new sublingual vaccine can boost the immune system's response in blood cells. This study aims to understand its effects on trained immunity.

Healthy Participants>2 yearsSafety phase (I)Efficacy phase (II)

Endometrial Cancer: New Treatment Combination

We are studying a new combination of a dual mTOR inhibitor and anastrozole for women with metastatic hormone receptor-positive endometrial cancer. The goal is to see if this combination works better than anastrozole alone.

Advanced and Metastatic CancerSafety phase (I)Efficacy phase (II)Gynecology and ObstetricsOncology

COVID-19 Booster: CD40.Pan.CoV Vaccine

We are testing a new vaccine to see if it safely boosts immunity in adults. This study will help us understand its effectiveness as a booster shot.

Healthy Participants1-2 yearsSafety phase (I)Infectious Diseases

Head and Neck Cancer: Niraparib and Dostarlimab Study

We are studying the effects of Niraparib and Dostarlimab combined with chemotherapy and radiotherapy in patients with locally advanced head and neck cancer. The goal is to see if this combination improves treatment outcomes compared to standard approaches.

Squamous Cell Carcinoma of the Head and Neck>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

HER2-Targeting Imaging for Cancer Patients

We are testing a new imaging method using a special drug to help identify HER2-positive tumors in cancer patients. This may improve how we detect and monitor cancer.

Breast Cancer and Gastroesophageal AdenocarcinomaSafety phase (I)Oncology

Metastatic Colorectal Cancer: Arfolitixorin Combination Therapy

We are studying a new treatment combining arfolitixorin with standard drugs for patients with metastatic colorectal cancer. The goal is to evaluate its safety and effectiveness in improving treatment results.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Solid Tumors: MK-3120 Treatment Study

We are testing a new treatment called MK-3120 for people with advanced solid tumors to see how safe it is and if it can help reduce tumor size.

Advanced Solid Tumor Disease>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

CAR-T Cell Therapy for Autoimmune Diseases

We are studying a new CAR-T cell treatment for patients with active autoimmune diseases like lupus, systemic sclerosis, and inflammatory myopathy. The trial aims to assess safety and how well this therapy works in reducing disease symptoms.

Systemic SclerosisSystemic Lupus ErythematosusIdiopathic Inflammatory Myopathy6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyNeurologyRheumatology

CD19+ Lymphoid Disease: CAR T-Cell Therapy

We are studying a new treatment using modified T cells for patients with relapsed or refractory CD19+ lymphoid diseases like leukemia and lymphoma. The goal is to see if this approach can safely reduce cancer and improve patient outcomes.

Acute Lymphoblastic Leukemia (ALL) RecurrentNon-Hodgkin's Lymphoma (NHL) Refractory>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyOncology

B-Cell Malignancies: MB-CART2219.1 Therapy

We are testing a new CAR T-cell therapy for adults and children with relapsed or refractory B-cell cancers. The study aims to find the right dose and evaluate its safety and effectiveness.

Relapsed/Refractory Lymphoma or ALL>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

B-Cell Malignancies: EXS73565 Treatment Study

We are testing a new medication for individuals with relapsed or refractory B-cell malignancies. This study aims to find the best dose to ensure safety and effectiveness.

B-cell MalignanciesSafety phase (I)HematologyOncology

Advanced Solid Tumors: MK-8294 Treatment

We are evaluating a new treatment called MK-8294 for people with advanced solid tumors. The study aims to understand its safety and how well it works.

Breast CancerCervical Squamous Cell CarcinomaEndometrial Carcinoma1-2 yearsSafety phase (I)Oncology

Parkinson's Disease: Investigational Drug ARV-102

We are studying the safety and effects of ARV-102 in patients with Parkinson's disease. This research aims to understand how well the drug is absorbed and its potential benefits.

Parkinson's Disease1-2 yearsSafety phase (I)Neurology

ADCE-D01 for Metastatic Soft Tissue Sarcoma

We are testing a new treatment called ADCE-D01 in patients with metastatic or unresectable soft tissue sarcoma. The study aims to evaluate its safety and how well it may help fight the cancer.

Soft Tissue Sarcoma1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Malaria Treatment: INE963 Study

We are investigating a new compound, INE963, to see how safe it is and how well it works for treating malaria. This study will help us understand how the body handles this new treatment.

Malaria6-12 monthsSafety phase (I)Infectious DiseasesInternal Medicine